Draft Guidance on Medroxyprogesterone Acetate

Contains Nonbinding Recommendations

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

**Active Ingredient:** Medroxyprogesterone acetate

**Dosage Form; Route:** Tablet; oral

**Recommended Studies:** Two studies

1. **Type of study:** Fasting  
   **Design:** Single-dose, two-way crossover in vivo  
   **Strength:** 10 mg  
   **Subjects:** Non-pregnant, non-lactating females, general population  
   **Additional comments:** None

2. **Type of study:** Fed  
   **Design:** Single-dose, two-way crossover in vivo  
   **Strength:** 10 mg  
   **Subjects:** Non-pregnant, non-lactating females, general population  
   **Additional comments:** None

**Analyte to measure (in appropriate biological fluid):** Medroxyprogesterone acetate in plasma

**Bioequivalence based on (90% CI):** Medroxyprogesterone acetate

**Waiver request of in vivo testing:** 2.5 mg and 5 mg strengths based on (i) acceptable bioequivalence studies on the 10 mg strength, (ii) proportional similarity of the formulations across all strengths, and (iii) acceptable in vitro dissolution testing of all strengths.

**Dissolution test method and sampling times:** The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods web site, available to the public at the following location: [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/). Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application.  
As per the reference listed drug labeling, all strengths of Medroxyprogesterone Acetate Tablets are scored. For additional information on the evaluation of scored tablets, refer to the FDA Guidance on *Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation.*

**Recommended Nov 2019**